发明授权
US07608271B2 Modified human immunodeficiency virus anti-fusogenic GP41 peptides comprising a maleimide-containing group
失效
包含含马来酰亚胺基团的修饰的人免疫缺陷病毒抗融合GP41肽
- 专利标题： Modified human immunodeficiency virus anti-fusogenic GP41 peptides comprising a maleimide-containing group
- 专利标题（中）： 包含含马来酰亚胺基团的修饰的人免疫缺陷病毒抗融合GP41肽
-
申请号： US10950010申请日： 2004-09-24
-
公开(公告)号： US07608271B2公开(公告)日： 2009-10-27
- 发明人: Dominique P. Bridon , Robert S. Dufresne , Nisssab Boudjellab , Martin Robitaille , Peter G. Milner
- 申请人： Dominique P. Bridon , Robert S. Dufresne , Nisssab Boudjellab , Martin Robitaille , Peter G. Milner
- 申请人地址： CA Montreal, Quebec
- 专利权人： Conjuchem Biotechnologies Inc.
- 当前专利权人： Conjuchem Biotechnologies Inc.
- 当前专利权人地址： CA Montreal, Quebec
- 代理机构： Lando & Anastasi, LLP
- 主分类号： A61K39/385
- IPC分类号： A61K39/385 ; A61K39/21
摘要：
Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
公开/授权文献
信息查询
